29,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Selegiline has a long-term beneficial effect in Alzheimer's disease on memory modalities that reflect the function of the prefrontal areas of the brain, which are rich in dopamine receptors. 5 key findings →
Participants: 143 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The objective of this study was to compare the effect of multisensory stimulation environment (MSSE) and one-to-one activity sessions in the symptomatology of elderly individuals with severe dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Short-term nutritional supplements enable an improvement in Alzheimer patients' nutritional status, but it remains to be seen whether they will be sufficient to improve long-term nutritional status. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Owing to the pharmacokinetic properties of physostigmine when administered by conventional routes, long-term cholinergic treatment of Alzheimer's disease is difficult to manage. 3 key findings →
Participants: 204 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
No clear conclusion can be drawn on the effectiveness of psychoactive cannabinoids in the treatment of psychiatric manifestations, in particular agitation and aggression, in AD. 2 key findings →
Design: randomized controlled trial Participants: 422 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The results of this study suggest that naftidrofuryl is effective and well tolerated in treating the symptoms of vascular and mixed dementia. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Conventional MCI criteria were insufficient to allow for the creation of well-defined and internationally comparable samples of MCI patients. 1 key finding →
Design: cohort study Participants: 395 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Donanemab and Lecanemab showed good efficacy in ADCS-ADL and CDR-SB, respectively. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Data collection will begin in four Canadian provinces (Alberta, Manitoba, Ontario and Saskatchewan) in February 2020 and is expected to be completed in June 2021. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Bacopa consumption is known to enhance cognitive performance in healthy individuals and is associated with alterations in pathways related to branched-chain and aromatic amino acid biosynthesis. 3 key findings →
Participants: 76 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This study was approved by the institutional review board in April 2022 and funded in May 2022. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
People with MCI are at increased risk of developing AD. 5 key findings →
Design: systematic review Participants: 51 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Trial registration ClinicalTrials.gov NCT04821960; https://clinicaltrials.gov/ct2/show/NCT04821960. 4 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The mean age was 72 years (49-90 years), and 44 (62%) patients were female. 1 key finding →
Participants: 71 Evidence: low
Full summary, score breakdown and related studies → Original source
Caregivers and neurologists considered incremental clinical benefit over SOC and safety to be highly desirable qualities for a new drug that could clear amyloid plaques and delay clinical progression and indicated a willingness to accept incremental ARIA-E to achieve additional clinical benefits. 2 key findings →
Participants: 137 Evidence: low
Full summary, score breakdown and related studies → Original source
CAARS has the potential to predict CAA severity; however, its clinical utility should be evaluated in follow-up studies. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Use of cholinesterase inhibitors is associated with increased rates of syncope, bradycardia, pacemaker insertion, and hip fracture in older adults with dementia. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
SSAE-3/5 scores correlated with BGTS scores, with high inter-reader intraclass correlation coefficients across all scales. 3 key findings →
Participants: 75 Evidence: low
Full summary, score breakdown and related studies → Original source
CAA-PRS was significantly associated with pathological CAA (OR = 1.766, p < 0.001), with an AUC of 0.783 overall and 0.766 (OR = 1.780, p = 0.002) in those with high amyloid burden. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Overall, 304 patients receiving cholinesterase inhibitors/memantine also received anticholinergics. 5 key findings →
Participants: 304 Evidence: low
Full summary, score breakdown and related studies → Original source
We found that 51.9% of DLB patients were ever prescribed a ChEI, and those who were prescribed a ChEI had a greater diagnosis interval. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Crenezumab is a humanized anti-amyloid-beta (Aβ) monoclonal IgG4 antibody in development for the treatment of Alzheimer’s disease (AD). 2 key findings →
Design: clinical trial Participants: 500 Evidence: high
Full summary, score breakdown and related studies → Original source
RVT-101 is a 5-hydroxytryptamine 6 (5-HT6) receptor antagonist for the treatment of dementia with a number of favorable properties including once daily dosing, lack of food effect, and low potential for drug interactions. 4 key findings →
Design: clinical trial Participants: 684 Evidence: high
Full summary, score breakdown and related studies → Original source
In total, 100 subjects completed the study. 5 key findings →
Design: clinical trial Participants: 100 Evidence: high
Full summary, score breakdown and related studies → Original source
Two‐hundred and sixteen only subjects were randomized across 28 French expert clinical sites. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 29,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 29,780 records, built mostly from automated pulls of Europe PMC (63.8% of the library) and OpenAlex (17.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,037 records (3.5% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →